Chimerix January 2022 Corporate Presentation Forward-Looking Statements 2 These slides contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include those relating to, among other things, the status of Chimerix's oncology programs, and the results of the 50-patient efficacy analysis of ONC201, including thos ...

Chimerix, Inc. (NASDAQ:CMRX) Q3 2021 Earnings Conference Call November 4, 2021 8:30 AM ET Company Participants Michelle LaSpaluto - Vice President of Strategic Planning and Investor Relations Mike Sherman - President and Chief Executive Officer Mike Andriole - Chief Financial and Business Officer Allen Melemed - Chief Medical Officer Josh Allen - Chief Technology Officer of Imipridones Conference Call Participants Maury Raycroft - Jefferies Joseph Thome - Cowen and Company Naureen Quibria - Maxim Group Soum ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35867 CHIMERIX, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 33-0903395 (State or Other Jurisdictio ...

Chimerix 2Q21 Corporate Presentation Forward-Looking Statements 2 These slides contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include those relating to, among other things, Chimerix's ability to develop and commercialize its drug candidates including ONC201, DSTAT and TEMBXA®; the sufficiency of the da ...

Chimerix, Inc. (NASDAQ:CMRX) Q2 2021 Earnings Conference Call August 5, 2021 8:30 AM ET Company Participants Michelle LaSpaluto - VP of Strategic Planning and IR Mike Sherman - President and CEO Mike Andriole - Chief Financial and Business Officer Allen Melemed - Chief Medical Officer Josh Allen - CTO, Imipridones Conference Call Participants Naureen Quibria - Maxim Group Joseph Thome - Cowen and Company Soumit Roy - JonesTrading Maury Raycroft - Jefferies Operator Good morning, ladies and gentlemen, and we ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35867 CHIMERIX, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 33-0903395 (State or Other Jurisdiction of ...

Chimerix, Inc. (NASDAQ:CMRX) Q1 2021 Earnings Conference Call May 6, 2021 8:30 AM ET Company Participants Michelle LaSpaluto – Vice President of Strategic Planning and Investor Relations Mike Sherman – President and Chief Executive Officer Allen Melemed – Chief Medical Officer Josh Allen – Chief Technology Officer-Imipridones Mike Andriole – Chief Scientific Officer Conference Call Participants Kevin Strang – Jefferies Naureen Quibria – Maxim Group Ed White – H.C. Wainwright Joe Thome – Cowen and Company So ...

May Corporate Update Forward-Looking Statements 2 These slides contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include those relating to, among other things, Chimerix's ability to develop its drug candidates including ONC201, DSTAT and BCV; the sufficiency of the data from the current clinical trial of ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35867 CHIMERIX, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 33-0903395 (State or Other Jurisdiction of ...

March Corporate Update Forward-Looking Statements These slides contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include those relating to, among other things, Chimerix's ability to develop its drug candidates including ONC201, DSTAT and BCV; the sufficiency of the data from the current clinical trial of ...